Skip to main content

Table 3 Results of base case cost-effectiveness of analysis

From: Cost-effectiveness of Human Papilloma Virus (HPV) vaccination in Nigeria: a decision analysis using pragmatic parameter estimates for cost and programme coverage

Name of strategy

Costs (US$)

Effectiveness (DALYs)

Incremental Costs

Incremental Effectiveness (DALY averted)

ICER (US$ / DALY averted)

Annual CC incidence per 100,000

Remark

Gavi vaccine price ($4.5/dose)

 CS

8.00

0.00427

–

–

–

17.08

–

 NS alone

10.27

0.00418

2.27

0.00009

–

16.52

Dom

 CS + NV

18.23

0.00298

10.23

0.00129

7930

11.52

R

 NS + NV

20.16

0.00292

1.93

0.00006

32,167

11.16

NR

Lowest vaccine price offered to public sector ($13/dose)

 CS

8.05

0.00431

–

–

–

17.09

–

 NS alone

10.31

0.00421

2.26

0.00010

–

16.53

Dom

 CS + NV

29.76

0.00305

21.71

0.00126

17,230

11.68

NR

 NS + NV

31.71

0.00299

1.95

0.00006

32,500

11.34

NR

Non Gavi vaccine price (CS + NV)

 $11/dose

27.02

0.00300

19.00

0.00128

14,845

11.64

NR

 $9/dose

24.25

0.00297

16.22

0.00133

12,202

11.52

NR

 $7/dose

21.58

0.00298

13.45

0.00136

9900

11.52

NR

 $5/dose

18.90

0.00301

10.72

0.00136

7897

11.57

R

Most efficient cervical cancer screening age (CS + NV)

 30 years

18.23

0.00298

10.23

0.00129

7933

11.52

R

 40 years

18.29

0.00303

10.20

0.00128

7947

11.79

R

 50 years

19.37

0.00306

10.26

0.00127

8116

11.73

R

  1. Cost-effectiveness threshold = US$ 9609.9/DALY averted
  2. \( \mathrm{ICER}=\frac{Strategy\kern0.5em \cos t\hbox{-} Current\kern0.5em scenario\kern0.5em \cos t}{Current\kern0.5em scenario\kern0.5em DALYs\kern0.5em lost\hbox{-} Strategy\kern0.5em DALYs\kern0.5em lost} \)
  3. CS current scenario of opportunistic screening, NS National cervical cancer screening, NV National HPV vaccination, DALY disability adjusted life years, CC cervical cancer, R recommended, NR not recommended, Dom Dominated